Skip to main content

Table 3 Effects of AbMIP and placebo on homocysteine (HCY), ADMA and HbA1c

From: Effects of an L-arginine-based multi ingredient product on endothelial function in subjects with mild to moderate hypertension and hyperhomocysteinemia - a randomized, double-blind, placebo-controlled, cross-over trial

 

Placebo

AbMIP

Product effect

Post supplementation

Post supplementation

p-value

cohens d

HCY [μmol/l]

11.95 ± 1.85 (11.19–12.72)

9.10 ± 1.94 (8.3–9.9)

<0.0001

2.415

ADMA μmol/l]

0.632 ± 0.088 (0.56–0.69)

0.638 ± 0.107 (0.59–0.68)

0.649

0.185

HbA1c [%]

5.34 ± 0.38 (5.19–5.50)

5.37 ± 0.41 (5.20–5.54)

0.846

0.210

  1. Results are presented as mean ± standard deviation (95% CI)
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us